Skip to content

Study · Systematic review · n = 2,413 · 2023

8 results

Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.

Bandyopadhyay S, Das S, Samajdar SS, Joshi SR

Diabetes & metabolic syndrome13 Sept 2023Cited by 52 (Europe PMC)

PMID37717295 (opens in a new tab)DOI10.1016/j.dsx.2023.102849 (opens in a new tab)PepBankPUB-37717295
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, semaglutide reduced serum alanine transaminase in a pooled analysis.

    In plain wordsIn pooled studies of people with fatty liver disease, semaglutide lowered the liver enzyme ALT.

    Peptide
    Semaglutide
    Outcome
    DecreaseSerum alanine transaminase change
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    mean difference
    14.07 U/L
    ALT reduction

    Source sentences

    Summary
    Semaglutide treatment showed a reduction in serum alanine transaminase [mean difference: 14.07 U/L (95% CI: 19.39 to -8.75); p < 0.001]
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, semaglutide reduced serum aspartate transaminase in a pooled analysis.

    In plain wordsIn pooled studies of people with fatty liver disease, semaglutide lowered the liver enzyme AST.

    Peptide
    Semaglutide
    Outcome
    DecreaseSerum aspartate transaminase change
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    mean difference
    6.89 U/L
    AST reduction

    Source sentences

    Summary
    aspartate transaminase [mean difference: 6.89 U/L (95% CI: 9.14 to -4.63); p < 0.001]
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, semaglutide significantly improved liver fat content in a pooled analysis.

    In plain wordsIn pooled studies of people with fatty liver disease, semaglutide reduced liver fat.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver fat content
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    mean difference
    4.97%
    liver fat content

    Source sentences

    Summary
    There was a significant improvement in liver fat content [mean difference: 4.97% (95% CI: 6.65 to -3.29); p < 0.001]
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
  4. 04HumanSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, semaglutide significantly improved liver stiffness in a pooled analysis.

    In plain wordsIn pooled studies of people with fatty liver disease, semaglutide reduced liver stiffness.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver stiffness
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    mean difference
    0.96 kPa
    liver stiffness

    Source sentences

    Summary
    and liver stiffness [mean difference: 0.96 kPa (95% CI: 1.87 to -0.04); p = 0.04].
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
  5. 05HumanSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, semaglutide significantly improved glycated hemoglobin in a pooled analysis.

    In plain wordsIn pooled studies of people with fatty liver disease, semaglutide improved long-term blood sugar control.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated hemoglobin level
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were significant improvements in the glycated hemoglobin level and the lipid profile.
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
  6. 06HumanSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, semaglutide significantly improved the lipid profile in a pooled analysis.

    In plain wordsIn pooled studies of people with fatty liver disease, semaglutide improved blood fat measures.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedLipid profile
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There were significant improvements in the glycated hemoglobin level and the lipid profile.
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
  7. 07HumanSystematic reviewSafety outcome

    In patients with NAFLD or NASH, the risk of serious adverse events was higher with semaglutide than with placebo.

    In plain wordsIn pooled studies of people with fatty liver disease, serious adverse events were more likely with semaglutide than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseSerious adverse events
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    relative risk
    1.54 ratio
    serious adverse events vs placebo

    Source sentences

    Summary
    the risk of serious adverse events [relative risk: 1.54 (95% CI: 1.02 to 2.34); p = 0.04]
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
  8. 08HumanSystematic reviewSafety outcome

    In patients with NAFLD or NASH, the most common serious adverse events with semaglutide were gastrointestinal and gallbladder-related diseases.

    In plain wordsIn pooled studies of people with fatty liver disease, the most common serious adverse events with semaglutide were digestive and gallbladder problems.

    Peptide
    Semaglutide
    Outcome
    Not applicableTypes of serious adverse events
    Study

    n = 2,413

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    the most common ones were gastrointestinal (nausea and vomiting, dyspepsia, decreased appetite, constipation, and diarrhea) and gallbladder-related diseases.
    1 context sentence
    Summary · context
    This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.